![](/img/cover-not-exists.png)
[BMJ Publishing Group Ltd ESGO Annual Meeting Abstracts - ()] Best Oral Communications/Late-Breaking Abstracts 3 â Ovarian Cancer - Phase III PAOLA-1/ENGOT-ov25 trial: olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer treated with platinum-based chemotherapy plus bevacizumab
Harter, P, Mouret-Reynier, MA, Pignata, S, Cropet, C, González-Martin, A, Bogner, G, Fujiwara, K, Vergote, I, Colombo, N, Mäenpää, J, Floquet, A, El-Balat, A, Lorusso, D, Guerra Alia, EM, Fabbro,DOI:
10.1136/ijgc-2019-esgo.10
File:
PDF, 87 KB